News | August 08, 2021
Cipla posts net profit at Rs 715 crores
India business contributes to a stellar performance
India business contributes to a stellar performance
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
This robust growth has come despite the raging pandemic for most part of the quarter
He will be stationed at the company HQ in Bengaluru, India
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Subscribe To Our Newsletter & Stay Updated
